American Radiolabeled Chemicals, Inc., Technical Data Sheet, “ART 549 Naltrindole, [5′, 7′-3H],” Feb,. 17, 1997. |
Campa et al., “Characterization of δ Opioid Receptors in Lung Cancer Using a Novel Nonpeptidic Ligand,” Cancer Research 56: 1965-1701, 1996. |
Chang et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” The Journal of Pharmacology And Experimental Therapeutics 267(1): 852-857, 1993. |
Channing et al., “Radiosynthesis of [18F]3-Acetylcyclofoxy: A High Affinity Opiate Antagonist,” Int. J. Appl. Radiat. Isot. 36(6): 429-433, 1985. |
Cohen et al., “F-18-Cyclofoxy PET Imaging In Man,” The Journal of Nuclear Medicine 29(5): p. 796, Abstract No. 228, 1988. |
Dannals et al. “Radiosynthetic of an Opiate Receptor Binding Radiotracer: [11C]Carfentanil,” Int. J. Appl. Radiat. Isot. 36(4), 303-306, 1985. |
Dasher et al., “Electrophilic Opioid Ligands. Oxygen Tethered α-Methylene-γ-lactone, Acrylate, Isothiocyanate, and Epoxide Derivatives of 6β-Naltrexol,” Journal of Medicinal Chemistry 35(13): 2374-2384, 1992. |
Frost et al., “Comparison Of C-11 Diprenorphine And C-11 Carfentanil Binding To Opiate Receptors In Man By PET,” The Journal of Nuclear Medicine 29(5): p. 796, Abstract No. 231, 1988. |
Frost et al., “Imaging Opiate Receptors in the Human Brain by Positron Tomography,” Journal of Computer Assisted Tomography 9(2): 231-236, 1985. |
Frost et al., “Multi-Compartmental Analysis Of C-11-Diprenorphine Binding To Opiate Receptors In Man By PET,” The Journal of Nuclear Medicine 29(5): p. 796, Abstract No. 230, 1988. |
Jones et al., “Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers,” Journal of Neuroscience Methods 23: 121-129, 1988. |
Koolpe et al., “Opioid Agonists and Antagonists. 6-Desoxy-6-substituted Lactone, Epoxide, and Glycidate Ester Derivatives of Naltrexone and Oxymorphone,” Journal of Medicinal Chemistry 28: 949-957, 1985. |
Lever et al., “Synthesis Of Carbon-11 Labeled Diprenorphine: A Radioligand For Positron Emission Tomographic Studies Of Opiate Receptors,” Tetrahedron Letters 28(35): 4015-4018, 1987. |
Lever et al., “Synthesis Of N1′-([11C]Methyl)Naltrindole ([11C]MeNTI): A Radioligand For Positron Emission Tomographic Studies Of Delta Opioid Receptors,” Journal of Labelled Compounds and Radiopharmaceuticals XXXVI(2): 137-145, 1995. |
Luthra et al., “The Preparation of Carbon-11 Labelled Diprenorphine: a New Radioligand for the Study of the Opiate Receptor System In vivo,” J. Chem. Soc. Chem. Commun.20: 1365-1456, 1995. |
Olmsted et al., “A Remarkable Change of Opioid Receptor Selectivity on the Attachment of a Peptidomimetic χ Address Element to the δ Antagonist, Natrindole: 5′-[N2-Alkylamidino)methyl]naltrindole Derivatives as a Novel Class of κ Opioid Receptor Antagonists,” J. Med. Chem. 36: 179-180, 1993. |
Otte et al., “Yttrium-90-labelled somatostatin-analogue for cancer treatment,” The Lancet 351: 417-418, 1998. |
Portoghese et al., “δ Opioid Antagonist Activity and Binding Studies of Regioisomeric Isothiocyanate Derivatives of Naltrindole: Evidence for δ Receptor Subtypes,” J. Med. Chem. 35(2): 4086-4091, 1992. |
Portoghese et al., “Application of the Message-Address Concept in The Design of Highly Potent and Selective Non-Peptide δ Opioid Receptor Antagonists,” Journal of Medicinal Chemistry 31(2): 281-282, 1988. |
Portoghese et al., “Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist,” European Journal of Pharmacology 146: 185-186, 1988. |
Portoghese et al., “Opioid Agonist and Antagonist Activities of Morphindoles Related to Naltrindole,” J. Med. Chem. 35: 4325-4329, 1992. |
Portoghese, “Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists,” TiPs 10: 230-235, 1989. |
Schmidhammer et al., “Synthesis And Biological Evaluation Of 14-Alkoxymorphinans. 14.1 14-Ethoxy-5-Methyl Substituted Indolomorphinans With δ Opioid Receptor Selectivity,” Bioorganic & Medicinal Chemistry Letters 7(2): 151-156, 1997. |
Vogel et al., “Cyclic morphiceptin analogs: cyclization studies and opioid activities in vitro,” Int. J. Peptide & Protein Res. 48: 495-502, 1996. |
Weerawarna et al., “Isothiocyanate-Substituted κ-Selective Opioid Receptor Ligands Derived from N-Methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]phenylacetamide,” Journal of Medicinal Chemistry 37(18): 2856-2864, 1994. |